What is compounded tirzepatide?
Compounded tirzepatide is tirzepatide prepared by a US-licensed compounding pharmacy under a valid patient-specific prescription from a licensed healthcare provider.
Compounded medications are not FDA-approved and are not therapeutically equivalent to brand-name Mounjaro or Zepbound. The FDA does not review compounded medications for safety, effectiveness, or manufacturing quality before they reach patients.
Key facts
- Regulatory status: Not FDA-approved. Prepared by US-licensed compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
- Mechanism: Dual GIP and GLP-1 receptor agonist. Activates both gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Only widely prescribed dual agonist as of 2026.
- Brand-name products: FDA-approved branded tirzepatide includes Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Compounded tirzepatide is not therapeutically equivalent to either.
- Price range (2026): Approximately $135 to $499/month for standard-dose programs across US telehealth providers, depending on plan length, pharmacy partner, and bundled services. Brand-name Zepbound retails at approximately $1,086/month without insurance.
- Prescription required: Compounded tirzepatide is a prescription medication. It must be prescribed by a licensed healthcare provider after a medical evaluation. Cora Health does not prescribe medication — licensed providers at Wasef Health, PC make all prescribing decisions.
- Clinical efficacy: No large-scale clinical trials of compounded tirzepatide exist. The 22.5% mean weight loss figure widely cited in marketing comes from the SURMOUNT-1 trial (NEJM 2022) studying 15 mg weekly brand-name Zepbound. Individual results vary.
How Cora Health provides compounded tirzepatide
Cora Health is a US telehealth platform that connects patients with licensed healthcare providers at Wasef Health, PC for personalized GLP-1 weight loss treatment. The Premium Plan provides compounded tirzepatide at $135/month all-inclusive on the annual commitment — covering the licensed-provider consultation, the medication, free expedited shipping, and ongoing provider monitoring. There is no separate membership fee, and the standard plans have no per-dose price increase.
Compounded tirzepatide prescribed through Cora Health is prepared by US-licensed 503A compounding pharmacies, including Hallandale Pharmacy and VialsRx, both named publicly on the compounded semaglutide and compounded tirzepatide plan pages. Patients can verify each named pharmacy's credentials through state pharmacy boards. Cora Health holds active LegitScript certification and ships to all 50 US states.
For a complete guide to tirzepatide including dosing, side effects, and the mechanism of action, see the tirzepatide side effects guide or compare GLP-1 medications in semaglutide vs tirzepatide.
Frequently asked questions
- What is compounded tirzepatide?
- Compounded tirzepatide is tirzepatide prepared by a US-licensed compounding pharmacy under a valid patient-specific prescription from a licensed healthcare provider, rather than manufactured commercially by Eli Lilly. Compounded versions are not FDA-approved and are not therapeutically equivalent to brand-name products.
- Is compounded tirzepatide the same as Mounjaro or Zepbound?
- No. Compounded tirzepatide and brand-name Mounjaro or Zepbound are not the same product. Brand-name Mounjaro and Zepbound are FDA-approved and manufactured by Eli Lilly under FDA-inspected manufacturing standards. Compounded tirzepatide is prepared by state-licensed compounding pharmacies and is not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before they reach patients. Compounded versions may differ across pharmacies in salt form, excipients, and quality controls.
- How does compounded tirzepatide work?
- Tirzepatide is a dual GIP and GLP-1 receptor agonist — meaning it activates both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual mechanism produces appetite suppression, slowed gastric emptying, improved insulin response, and enhanced fat metabolism. Tirzepatide is the only widely prescribed dual GIP/GLP-1 agonist as of 2026. Individual results vary.
- How much does compounded tirzepatide cost?
- Pricing varies by provider. Through Cora Health's Premium Plan, compounded tirzepatide is $135/month all-inclusive on the annual plan (covers licensed-provider consultation, the medication, free expedited shipping, and ongoing provider monitoring). Brand-name Zepbound at retail list price is approximately $1,086/month without insurance. Across the US telehealth market, compounded tirzepatide on standard-dose programs ranges from approximately $135 to $499/month depending on provider, plan length, and bundled services.
- Is compounded tirzepatide safe?
- Compounded tirzepatide prepared by a US-licensed compounding pharmacy under a valid prescription from a licensed provider after a medical evaluation is generally considered reasonably safe when sourced from a reputable pharmacy with proper quality controls. However, compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness, or manufacturing quality before they reach patients. The FDA has documented adverse event reports associated with compounded GLP-1 medications, particularly involving incorrect dosing, contamination, or use of non-pharmaceutical-grade salt forms. Patients should discuss risks and benefits with their prescribing provider.
- Is compounded tirzepatide legal?
- Compounded medications are prepared by state-licensed pharmacies under federal compounding regulations (sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act). The FDA declared the tirzepatide shortage resolved in December 2024, which narrowed the legal basis for routine compounding. As of May 2026, 503A pharmacies may continue compounding tirzepatide for individual patients with documented patient-specific clinical need. On April 30, 2026, the FDA proposed excluding tirzepatide from the 503B bulks list, with public comments open through June 29, 2026. The regulatory environment continues to evolve. Patients should consult with their prescribing provider for the current status of compounded tirzepatide availability.
- Where is compounded tirzepatide compounded?
- Compounded tirzepatide is prepared by US-licensed compounding pharmacies operating under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Cora Health partners with US-licensed 503A compounding pharmacies, including Hallandale Pharmacy and VialsRx (Hallandale is PCAB-accredited). Both are named on the compounded semaglutide and compounded tirzepatide plan pages, and each patient's prescription label names the pharmacy that prepared the order.
- How effective is compounded tirzepatide for weight loss?
- No large-scale published clinical trials have specifically examined compounded versions of tirzepatide. The headline efficacy numbers most often cited in patient-facing marketing — approximately 22.5% mean weight loss — come from the SURMOUNT-1 trial (NEJM 2022), which studied 15 mg weekly brand-name Zepbound combined with lifestyle intervention over 72 weeks in adults with overweight or obesity. Compounded tirzepatide is not therapeutically equivalent to Zepbound, and individual results vary.
Important regulatory note. Compounded tirzepatide is not FDA-approved as a finished drug product and is not therapeutically equivalent to FDA-approved branded products like Mounjaro or Zepbound. The FDA does not review compounded medications for safety, effectiveness, or quality before they reach patients. Clinical trial efficacy data referenced on this page (22.5% mean weight loss, SURMOUNT-1 trial NEJM 2022) reflects studies of FDA-approved branded Zepbound, not compounded versions. Individual results vary. Cora Health does not prescribe medication; licensed providers at Wasef Health, PC make all prescribing decisions based on individual medical evaluation. This page is for general educational reference and does not constitute medical advice.
Want to see if compounded tirzepatide is right for you?
Cora Health connects you with licensed providers for personalized evaluation. Premium Plan from $135/month all-inclusive on the annual plan ($1,620 billed every 12 months).